Preparation for the prevention and/or treatment of vascular disorders

• US 8,377,912 B2
• Filed: 08/09/2010
• Issued: 02/19/2013
• Est. Priority Date: 05/08/2000
• Status: Expired due to Term

• Current Assignee: nv nutricia
• Original Assignee: nv nutricia
• Inventors: Kiliaan, Amanda Johanne, Hageman, Robert Johan Joseph
• Primary Examiner(s): DAVIS, RUTH A
• Application Number:
  US12/853,001
• Publication Number:
  US 20100303784A1
• Time in Patent Office: 925 Days
• Field of Search: 514/165, 514/494, 514/560, 514/551, 514/882, 424/725, 424/752, 530/350
• US Class Current: 514/165
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23L 33/115 Fatty acids or derivatives thereof; Fats or oils
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23L 33/16 Inorganic salts, minerals or trace elements
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/032 Citric acid
• CPC Class Codes: A23V 2250/156 Mineral combination undefined extract A23V2250/1638
• CPC Class Codes: A23V 2250/161 Magnesium
• CPC Class Codes: A23V 2250/1642 Zinc
• CPC Class Codes: A23V 2250/1842 Lecithin
• CPC Class Codes: A23V 2250/1846 Phosphatidyl Choline
• CPC Class Codes: A23V 2250/1848 Phosphatidyl Ethanolamine
• CPC Class Codes: A23V 2250/1852 Phosphatidyl Serine
• CPC Class Codes: A23V 2250/5114 Dextrins, maltodextrins
• CPC Class Codes: A23V 2250/704 Vitamin B
• CPC Class Codes: A23V 2250/7052 Vitamin B6
• CPC Class Codes: A23V 2250/706 Vitamin B12
• CPC Class Codes: A23V 2250/716 Vitamin M
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/14 Quaternary ammonium compounds, e.g. edrophonium, choline betaines A61K31/205
• CPC Class Codes: A61K 31/194 : having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• CPC Class Codes: A61K 31/20 : having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/202 : having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/205 : Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/355 : Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/4415 : Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/519 : ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/683 : Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 : one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 33/30 : Zinc; Compounds thereof
• CPC Class Codes: A61K 33/34 : Copper; Compounds thereof
• CPC Class Codes: A61K 36/16 : Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives

Abstract

The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions:

• • fraction a) consisting of long chain polyunsaturated fatty acids;
  • fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine.
  • fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

Claims

1. A method for treating a person suffering from or at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes, comprising administering to a person in need thereof a preparation, comprising:

a) at least 120 mg long chain polyunsaturated fatty acid fraction comprising docosahexaenoic acid (DHA);

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) at least one factor in methionine metabolism selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium, zinc, and equivalents thereof.

2. The method of claim 1 for prevention and/or treatment of dementia syndromes.

3. The method of claim 1, wherein the degeneration of cerebral function, cognitive degeneration and/or dementia syndrome comprises Alzheimer'"'"'s disease, presenile dementia, senile dementia, atherosclerotic dementia, Parkinson'"'"'s or Huntington'"'"'s disease.

4. The method of claim 1, wherein the preparation comprises 50-2000 mg per daily dosage of DHA.

5. The method of claim 1, wherein the preparation further comprises eicosapentaenoic acid (EPA).

6. The method of claim 1, wherein fraction c) comprises folic acid, vitamin B6 and/or vitamin B12.

7. The method of claim 6, wherein fraction c) comprises folic acid and vitamin B6.

8. The method of claim 1, wherein the preparation comprises folic acid in an amount of at least 200 μ

g per daily dosage.

9. The method of claim 8, wherein the preparation comprises folic acid in an amount of at least 400 μ

g per daily dosage.

10. The method of claim 1, wherein the preparation comprises vitamin B6 in an amount of at least 2 mg per daily dosage.

11. The method of claim 1, wherein the preparation comprises vitamin B12 in an amount of at least 2 μ

g per daily dosage.

12. The method of claim 1, wherein fraction b) comprises phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine.

13. The method of claim 1, wherein the preparation comprises phospholipids in an amount of at least 0.2 g.

14. The method of claim 1, wherein fraction a) further comprises linoleic acid and/or α

-linoleic acid.

15. The method of claim 14, wherein the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of linoleic acid and a-linolenic acid is larger than 0.1:

1.

16. The method of claim 15, wherein the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of linoleic acid and a-linoleic acid is larger than 0.4:

1.

17. The method of claim 1, wherein the preparation further comprises at least one of a citrate or citric acid.

18. The method of claim 1, wherein the preparation further comprises huperzine A.

19. The method of claim 1, wherein the preparation further comprising at least one member selected from the group consisting of S-adenosylmethionine, choline, betaine, zinc and copper.

20. The method of claim 1, wherein fraction c) further comprises zinc and copper.

21. The method of claim 20, wherein the zinc and copper are present in a weight ratio of zinc to copper between 5 and 12.

22. The method of claim 1, wherein the preparation further comprises at least one member selected from the group consisting of camitine, vitamin B1, vitamin B5 and coenzyme Q10.

23. The method of claim 1, wherein the preparation further comprises lipophylic thiamine source, taurine, gamma-amino butyric acid, and/or derivatives thereof.

24. The method of claim 1, wherein the preparation further comprises at least one antioxidant selected from the group consisting of vitamin C, vitamin E, lipoic acid, selenium salts and carotenoids.

25. The method of claim 1, wherein the preparation further comprises an extract of ginkgo biloba.

26. The method of claim 1, wherein the preparation comprises:

at least 120 mg of long chain polyunsaturated fatty acids, at least 50 mg of which comprises DHA;

at least 200 mg phospholipids;

at least 200 μ

g folic acid; and

at least 500 mg citrate.

27. The method of claim 1, wherein fraction a) further comprises one Ω

-6 fatty acid selected from dihomogammalinolenic acid (DHGLA) and arachidonic acid (AA).

28. The method of claim 1 for treating a person suffering from or at risk of cognitive degeneration.

29. The method of claim 1, wherein the preparation comprises 120-2000 mg per daily dosage of EPA and DHA, collectively.

30. A method for treatment of vascular disorders or disorders associated therewith, comprising administering to a person in need thereof a preparation, comprising:

a) at least 120 mg long chain polyunsaturated fatty acid fraction comprising docosahexaenoic acid (DHA);

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) at least one factor in methionine metabolism selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium, zinc, and equivalents thereof.